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Background: Polyunsaturated fatty acid (PUFA) metabolism abnormalities have been long implicated in the
etiology of schizophrenia. Although several randomized clinical trials have been carried out to assess the efficacy
of omega-3 PUFA as add-on therapy in reducing psychopathology in populations of chronic patients with
schizophrenia, only a few concern first-episode schizophrenia. The majority of these studies used a 12-week
intervention based on ethyl-eicosapentaenoic acid (ethyl-EPA), however, with conflicting results. An intervention
based on docosahexaenoic acid plus EPA has not been used in first-episode schizophrenia studies so far. No
add-on supplementation studies have been carried out in medicated first-episode schizophrenia patients to assess
the efficacy of omega-3 PUFA in preventing relapses.
Methods: A randomized placebo-controlled one-center trial will be used to compare the efficacy of 26-week
intervention, composed of either 1320 mg/day of EPA and 880 mg/day of DHA, or olive oil placebo with regard to
symptom severity and relapse rate in first-episode schizophrenia patients. Eighty-two patients (aged 16–35) will be
recruited for the study. Eligible patients will be randomly allocated to one of two intervention arms: an active arm
or a placebo arm (olive oil). The primary outcome measure of the clinical evaluation is schizophrenia symptom
severity measured by the Positive and Negative Syndrome Scale (PANSS). Other outcomes include depressive
symptoms, patient functioning and the level of insight. Correlates of change measured during the study will include
structural brain changes, oxidative stress and defense, as well as neuroplasticity indicators. Metabolic syndrome
components will also be assessed throughout the study.
Discussion: By comparing 26-week administration of EPA + DHA or (placebo) olive oil as add-on therapy in
reducing symptom severity and one-year relapse rate in patients with first episode schizophrenia, it is intended to
provide new insights into the efficacy of omega-3 PUFA and correlates of change, and contribute to the improvement
of mental health care for individuals suffering from schizophrenia.
Trial registration: This study has been registered at Clinical Trials.gov with the following number: NCT02210962.
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Polyunsaturated fatty acids in schizophrenia
Schizophrenia is a neurodevelopmental and neurodegen-
erative disorder displaying disturbance in multiple neuro-
transmission pathways. Since polyunsaturated fatty acids
(PUFA) are essential for normal neurodevelopment, dis-
turbances of PUFA metabolism may be involved in the eti-
ology of neurodevelopmental disorders like schizophrenia
[1]. PUFA are the major constituents of cell membrane
phospholipids and take part in numerous biological
processes including receptor binding, neurotransmission,
signal transduction and the synthesis of active metabolites
(i.e. eicosanoids), which control inflammation, oxidative
stress and defense processes, among others. PUFA are
abundant in the central nervous system, where they are
the main constituents of neuronal membrane phospho-
lipids. Long-chain PUFA, i.e. docosahexaenoic acid (DHA)
and arachidonic acid (AA) are incorporated in Sn-2 pos-
ition of phospholipids. DHA and AA are released from
membrane phospholipids by phospholipase A2, and their
derivatives take part in neuronal impulse transmission.
Neuronal membranes are rich in DHA, which is essential
for normal brain development [2]. The DHA/AA (n-3/n-
6) ratio is important in the maintenance of an appropriate
level of biological membrane fluidity, which is in turn,
essential for ion channel function, membrane receptor
activity and the release of neurohormones, i.e. the signal-
ing processes of every cell. Numerous neurotransmission
pathways have been found to be dysfunctional in schizo-
phrenia, which raises the probability that membrane phos-
pholipids that modulate the activity of both receptors and
are involved in signal transduction may be part of the eti-
ology of schizophrenia.
PUFA metabolism disturbances have repeatedly been
described in patients with schizophrenia. Deficiencies of
PUFA were described in red blood cell (RBC) mem-
branes of patients with schizophrenia [3-6]. PUFA RBC
concentration is known to reflect its concentration in
the brain in adult humans [7]. Disturbances in PUFA me-
tabolism have been shown to exist even at early stages of
schizophrenia prior to initiation of antipsychotic therapy
[3] and in individuals at ultra-high risk of psychosis [8]. A
recent meta-analysis confirms the presence of n-3 and
omega-6 (n-6) PUFA abnormalities in antipsychotic-
naive, antipsychotic-free schizophrenia patients and in
patients currently treated with antipsychotics [9]. Post-
mortem brain studies have revealed decreased levels of
PUFA, especially docosahexaenoic acid and arachidonic
acid, in the frontal lobes of schizophrenia patients.
PUFA deficiencies in neuronal membranes can be the
result of the increased release of PUFA from membrane
phospholipids, or its decreased incorporation within
them. Both processes were found to be defective in
schizophrenia patients.Since PUFA cannot be effectively synthesized in humans,
decreased incorporation may be the result of dietary defi-
ciencies. One of our recent studies identified differences in
declared PUFA consumption between UHR individuals
who converted to full-threshold psychosis and who did not
develop psychotic disorder (article submitted for publica-
tion). Differences were also found in declared PUFA con-
sumption between healthy controls (HC), UHR individuals
and patients with first-episode schizophrenia (FES). The
PUFA consumption patterns of UHR individuals were
comparable with those of FES patients and were signifi-
cantly different from HC subjects: UHR and FES groups
declared significantly higher consumption of omega-6
fatty acids than the HC group.
Membrane phospholipids hypothesis of schizophrenia
The repeated observation of lipid metabolism dysfunctions
in patients with schizophrenia led to the formulation of the
Membrane Phospholipid Hypothesis of Schizophrenia by
David Horrobin [10], according to which, cellular PUFA
abnormalities can lead to schizophrenia in susceptible indi-
viduals. A number of pathophysiological changes observed
in schizophrenia can be related to PUFA metabolism: eg.
decreased membrane fluidity [11], altered monoaminergic
neurotransmission [12-14], production of proinflammatory
cytokines, increased oxidative stress damage to the neur-
onal membrane and reduced anti-oxidative defense [15].
PUFA depletion in schizophrenia can be a result of in-
creased phospholipase A2 activity and oxidative damage,
which together lead to increased release of PUFA from
neuronal membranes [16]. Phospholipase A2 (PLA2) gene
polymorphisms have been associated with susceptibility to
schizophrenia [17,18] and antipsychotic medications have
been found to decrease PLA2 expression in patients with
schizophrenia [19]. Another mechanism influencing PUFA
levels in the cell membranes of schizophrenia patients is
decreased incorporation of PUFA into membrane phos-
pholipids due to lipoprotein lipase dysfunction and inad-
equate synthesis of long-chain PUFA from their essential
precursors: linoleic acid (LA) for n-6 PUFA and alpha-
linolenic acid (ALA) for n-3 PUFA [20].
Efficacy of n-3 PUFA in schizophrenia
Supplementation studies in schizophrenia
Observations of PUFA metabolism dysfunctions in schizo-
phrenia patients at different stages of disease together as
well as those with PUFA dietary deficiencies prompted
intervention trials. Seven randomized controlled trials
(RCTs) comparing n − 3 PUFA eicosapentaenoic acid
(EPA) with placebo as supplemental treatment to anti-
psychotics in schizophrenia have been reported. Two of
these studies report that EPA had a positive effect on
primary efficacy [21,22], and all but one [23] of the others
reported at least some beneficial effect on secondary
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tients over 12 weeks found EPA to decrease time to
response in patients with non-affective psychosis, and
showed a 20% reduction in antipsychotic use in the EPA
augmented group [26]. A recent meta-analysis of RCTs
revealed no beneficial effect of EPA augmentation on
symptom severity in schizophrenia. However, no conclu-
sion could be drawn regarding the medium- to long-term
effects of EPA in schizophrenia, particularly regarding re-
lapse prevention in the early course of psychotic disorders
[27]. Moreover, a 12-week RCT conducted in individuals
at high clinical risk of schizophrenia provides prelimin-
ary evidence that intervention composed of 1.2 g of
PUFA (i.e. EPA + DHA) could prevent transition to
first-episode psychosis.
Supplementation with n-3 PUFA may demonstrate
higher efficacy in populations of individuals at high-risk
of psychosis and early psychosis than in patients with
chronic schizophrenia. A recent study notes that PUFA
metabolism disturbances are present relatively early in
the course of schizophrenia and diminish over time as the
disease progresses, and that treatment with antipsychotic
medications (aripiprazole and risperidone) was able to
correct aberrant PUFA levels in first-episode schizophre-
nia patients, but not in a group of patients with chronic
schizophrenia [28]. This suggests that intervention with n-
3 PUFA can be more effective when administered early in
the course of disease.
PUFA and the reduced risk of such adverse effects as
tardive dyskinesia and metabolic side effects associated
with antipsychotics
A growing body of evidence suggests that n-3 PUFA
may play a role in reducing the intensity of adverse effects
associated with antipsychotics. Antipsychotic-induced dys-
lipidemia was successfully treated with n-3 PUFA supple-
mentation [29]. Short term (6 weeks) n-3 supplementation
was able to modulate cardiometabolic risk factors in pa-
tients treated with olanzapine and either valproate or
lithium [30]. Berger et al. report that ethyl-EPA supple-
mentation used as add-on therapy in patients with
schizophrenia was associated with a 20% reduction in
the use of antipsychotics, reduced percentage of patients
experiencing the extrapyramidal side effects, constipa-
tion and the sexual side effects of antipsychotic therapy
[26]. Additionally, n-3 PUFA supplementation has been
shown to play a possible role in reducing the risk of tard-
ive dyskinesia [22], however, these observations are not
consistent [25]. Reduction of motor side effects of antipsy-
chotics have also been observed in animal models [31-33].
Reduction in the intensity of side effects associated with
n-3 supplementation can increase adherence to antipsy-
chotics and in turn, influence the severity of symptoms
and the relapse rate in first episode schizophrenia.Relapse in schizophrenia
Relapse in schizophrenia
It is estimated that up to 90% of individuals developing
first-episode schizophrenia achieve remission from symp-
toms in the first 12 months of therapy [34] but recovery
defined as attainment of both functional and symptomatic
remission for 2 years [35] is achieved in only 10-20% of
patients [36]. This is partly because a great number of pa-
tients will experience a relapse of psychotic episodes dur-
ing the first years following diagnosis. Longitudinal studies
find that about one third of patients will have experienced
a relapse before 1 year after recovery, and two thirds be-
fore 2 years [37,38]. Seventy to eighty percent of patients
experience relapse within three to five years [39]. There is
some evidence that with recurring episodes of psychosis,
the time to obtain response increases and the proportion
of patients achieving remission diminishes [40]. Psychotic
relapse and incomplete recovery can lead to the chronic
phase of the disease. Neurodegeneration and deterioration
occurs mainly in the first 5–10 years of illness. The long-
term outcome of the disease may be associated with the
number of relapses and the quality of remission achieved
[40]. These observations have generated increased interest
in relapse prevention in schizophrenia and have prompted
repeated attempts to understand the risk factors respon-
sible for recurrence of the psychotic exacerbation.
Relapse risk factors
A systematic review based on a meta-analysis of clinical
trials revealed that the risk of relapse in schizophrenia
decreases with antipsychotic medication use [41], and
the main risk factor for relapse is antipsychotic therapy
discontinuation [38,40]. The main reason for antipsychotic
non-adherence are safety and tolerability issues, as well as
lack of insight associated with psychosis. Although second
generation antipsychotics are frequently used in treat-
ment of patients diagnosed with schizophrenia, they are
associated with a high risk of adverse cardiometabolic
effects such as weight gain, glucose intolerance and
diabetes, and lipid profile abnormalities. A recent study
has found that both duration of relapse and the intensity
of treatment with antipsychotics may be associated with
brain volume loss [42]. Andreasen et al. found that the
duration of relapse was closely related to loss of brain
tissue over time in multiple brain regions, including
total cerebral volume loss, as well as loss in subregions,
particularly the frontal lobes. They report that relapse
duration and treatment intensity both contribute to brain
tissue loss, but while treatment effects are more diffusely
distributed, the relapse effects are most strongly associated
with changes to the frontal lobe tissue. The authors
conclude that relapse prevention should be sustained
using the lowest possible medication dosages to control
the symptoms.
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To date, only one study of the use of n-3 PUFA in relapse
prevention has been reported. Emsley et al. recently pub-
lished the results of a study assessing the efficacy of inter-
vention composed of 1 g of DHA and 2 g of EPA plus
300 mg of the antioxidant alpha-liopic acid (LA) or pla-
cebo in patients diagnosed with schizophrenia, schizoaf-
fective disorder or schizophreniform disorder meeting the
criteria of relapse in whom antipsychotic therapy was ta-
pered and discontinued according to the current guide-
lines. The study was terminated prematurely due to the
severity of some of the relapse episodes, as well as the high
relapse rates in both treatment groups: 90% and 75% in
active and placebo groups respectively. The authors did
not observe significant differences in relapse rates between
the study arms. The study concludes that n-3 PUFAs +
alpha-LA does not appear to be a suitable alternative to
maintenance antipsychotic treatment in relapse preven-
tion. The authors argue that on the basis of their findings,
the current treatment guidelines suggesting antipsychotic
discontinuation 2–3 years after the first psychotic episode
should be revised [43].
Rationale for the study
Hence, there is a growing body of evidence based on
animal models, in vitro and observational studies, as well
as from randomized clinical trials, which suggests that
n-3 PUFA plays a role in the pathophysiology of schizo-
phrenia, and that supplementation with these essential
compounds may be worth consideration, especially at
early stages of the disorder. N-3 PUFA supplementation
was found to be effective in reducing the risk of transi-
tion into psychosis in individuals at ultra-high risk of
psychotic disorders. Data from basic studies indicates
that PUFA metabolism impairments are present at early
stages of schizophrenia. However, meta-analyses of RCTs
do not indicate that n-3 PUFA may be efficacious in
reducing the severity of symptoms in chronic schizo-
phrenia patients: antipsychotic medications are still the
mainstay of schizophrenia therapy.
The number of schizophrenia patients treated with
antipsychotic polypharmacotherapy is increasing [44], des-
pite there being insufficient evidence from well-designed
clinical trials and in spite of accumulating data implicating
several serious adverse effects and increased health costs
associated with antipsychotic polytherapy [45]. Despite in-
creasing antipsychotic usage, more than 80% of patients
experience relapse within the first 5 years following the
first psychotic episode and the majority of deterioration
takes place during the first few years after diagnosis.
Unplanned antipsychotic discontinuation was shown to
be the main risk factor for relapse in schizophrenia [40].
However, Andreasen et al. report brain volume loss to
be associated not only with the duration of psychosis,including relapses, but also with the intensity of anti-
psychotic utilization [42]. Hence, it is particularly import-
ant that the smallest possible doses of antipsychotics are
used to reduce the duration of psychotic episodes in
schizophrenia, including relapses. To this end, n-3 sup-
plementation was shown to be safe and well tolerated
[46], and can allow reduced doses of antipsychotic med-
ications to be used to achieve and sustain remission in
schizophrenia [26].
Most previous studies assess the short-term efficacy
of n-3 fatty acids in the exacerbation of chronic schizo-
phrenia, but few of them have been conducted in a
population of first-episode schizophrenia patients. The
intervention period was 8 weeks in the majority of
studies. It is well established that the period needed to
refill the n-3 fatty acid store in the human body, and
hence to achieve maximum metabolic effects, is about
3–4 months. Most studies assess an intervention com-
posed of only EPA, one study compared EPA and DHA
in two separate study arms and only one study used a
mixture of EPA + DHA. The only study that reports an
intervention composed of EPA + DHA was conducted
in ultra-high risk patients.
It is important to underline that most reported studies
were carried out in chronic schizophrenia patients, while
only two of them supplemented first-episode patients.
Moreover, the majority of the RCTs conducted so far are
based on ethyl-eicosapentaenoic acid (ethyl-EPA) and
most interventions were short term, i.e. 8–12 weeks. DHA
is an important constituent of neuronal membranes,
which have an important role in brain development and
function. The DHA molecule itself has unique structural
properties that appear to provide optimal conditions for a
wide range of cell membrane functions. Its presence in the
neuronal membranes provides a biochemical and biophys-
ical basis for membrane fluidity and neurotransmission. In
addition, it was recently found to be a source of two
important endogenous neuroprotective compounds: pro-
tectins and resovlins.
One rudimentary source of DHA is marine algae, but
it can be found in a concentrated form in fish and mar-
ine oils. Mammalian cells lack the specific enzymes re-
quired for the de novo synthesis of alpha-linolenic acid
(ALA), the precursor for all n-3 fatty acid syntheses. The
endogenous synthesis of DHA from ALA in humans is
much more limited than previously assumed, and low
consumption of fish and marine oils can lead to DHA
deficiencies. In addition, the excessive consumption of
omega-6 fatty acids in the modern Western diet further
displaces DHA from membrane phospholipids. An
emerging body of research suggests that DHA plays a
unique role in neurodevelopment [47,48] and the pre-
vention of neuropsychiatric [49] and neurodegenerative
disorders [50,51].
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ized, placebo-controlled, single site study of a EPA +DHA
intervention in first-episode schizophrenia patients. The
efficacy of EPA + DHA added-on to antipsychotics in re-
ducing psychopathology and the relapse rate in early
schizophrenia have not yet been studied systematically.
The OFFER study aims to systematically evaluate the
long-term efficacy of n-3 PUFA in reducing psychopath-
ology and preventing relapse in patients with first-
episode schizophrenia.
Main research questions and hypotheses
The following research questions were formulated:
1. Is supplementation with n-3 fatty acids added to
antipsychotic medications an efficacious intervention
for patients in the acute phase of first-episode
schizophrenia?
2. Can add-on therapy with n-3 fatty acids initiated in
the acute phase of disease be efficacious in reducing
the one-year relapse rate in first-episode
schizophrenia.
3. Is add-on therapy with n-3 PUFA related to changes
in cognitive performance of first-episode schizophrenia
patients?
4. What are the biochemical and structural brain
correlates of n-3 PUFA add-on therapy in
first-episode schizophrenia patients? Specifically,
are oxidative stress and defense as well as brain
plasticity mechanisms involved? Is add-on n-3 PUFA
supplementation associated with structural brain
changes concerning gray and white matter, such




The study will be based on a randomized, double-blind,
placebo-controlled, parallel-group single-center augmen-
tation trial (RCT) of either 2.2 g per day of n-3 PUFA,
or olive oil placebo, added on to an adjustable dose of
antipsychotic medication. The background antipsychotic
therapy will be chosen and titrated according to the Pol-
ish standards of pharmacotherapy of mental disorders
[52]. The use of benzodiazepines (diazepam, lorazepam,
alprazolam, clonazepam), chlorprothixene, zuclopenthixol
acetate will be allowed if control of behavioral symptoms
is indicated. Zolpidem and zopiclone will be used in pa-
tients complaining of insomnia. For patients presenting
significant depressive symptoms the use of selective sero-
tonin reuptake inhibitors will be allowed. For all partici-
pants, the protocol allows for treatment of emergent
extrapiramidal side effects with biperiden and treatment
of akathisia with propranolol, lorazepam, or clonazepam.Using PUFA supplements other than contained in study
medication will not be permitted throughout the study.
Participant sample
The intended study population is composed of inpatients
admitted to the Psychiatric Clinics of the Central Teach-
ing Hospital, Medical University of Lodz. Patients will be
enrolled consecutively as they are admitted to the hos-
pital. Eligible patients will be (1) aged 16–35, (2) diag-
nosed with first-episode schizophrenia according to the
International Classification of Diseases 10th version
(ICD-10), which is an obligatory classification of mental
disorders in Poland, (3) currently psychotic as reflected
by the presence of at least one psychotic symptom daily
for more than one week (delusions, hallucinations, dis-
orders of thought form other than simple acceleration
or retardation, and disorganized, bizarre, or markedly
inappropriate behavior). Diagnosis will be confirmed by
the mini neuropsychiatric interview plus (MINI plus)
[53]. Patients will be excluded if more than two years have
passed since the onset of positive symptoms, if the patient
have bleeding disorders, or have been taking fish oil sup-
plements or anticoagulants for any reason, were diagnosed
with drug-induced psychosis, first-episode mania or or-
ganic disorders presenting with psychotic symptoms, if
the patient has a history of intellectual disability, or a his-
tory of head injury with loss of consciousness, or any
acute or unstable medical condition.
The trial procedures will be explained verbally and in
writing to all eligible patients. All participants will pro-
vide written informed consent prior to study enrollment.
The study will be conducted in accordance with the
Declaration of Helsinki and the study protocol has been
approved by the Ethics Committee of the Medical Uni-
versity of Lodz.
Power calculation
Previous studies have suggested medium effect sizes in
favor of n-3 fatty acids [21,22]. On the basis of previous
studies, we assume that there will be a nontrivial correl-
ation between baseline and outcome scores at follow-up,
and it is hypothesized that baseline scores will explain
25% of the variation in outcome measures. Power calcu-
lation revealed that 36 participants per study arm will
result in 80% power to detect medium effect size (0.3) at
a significance level of 0.05 (two sided). Assuming an at-
trition rate of 15%, we aim to enroll 82 patients.
Randomization and procedure
The study medication (omega-3 PUFA and placebo) will
be provided by Marinex International Sp. z o.o. and
shipped from Scandinavian Laboratories, Inc. Mt. Bethel,
PA, USA. It will be sent to the store of the Central
Teaching Hospital of the Medical University of Lodz,
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envelopes for unblinding in case of a serious adverse
event. Patients will be allocated the lowest available num-
ber of the randomization code list, and the Clinical Trial
Store will dispense bottles of study medication according
to the allocated number. Each bottle contains capsules of
study medication, i.e. either 1320 mg/day of EPA plus
880 mg/day of DHA or an equal amount of an olive oil
placebo. Both placebo and active capsules contain an anti-
oxidant, i.e. 0.2% alpha-tocopherol (vitamin E). The pla-
cebo contains also a scant amount of fish oil to provide a
comparable taste of the different capsules. The key to the
randomization list will remain with Marinex International
Sp. z o.o. until the last study participant completes the
trial. Both the patients and the study staff responsible
for study assessments will remain blind to the status of
the patients throughout the study. Participants will be
assessed by a registered dietician (ET) and advised to
adhere to a balanced diet for the duration of the study.
Interventions
Rationale for intervention arms
Early studies of red blood cell membranes in patients di-
agnosed with schizophrenia found deficiencies of both
n-3 and omega-6 fatty acids, especially arachidonic acid
(AA) and docosahexaenoic acid (DHA). Similar findings
were found by post mortem studies of the frontal lobes
of patients. The formulation of the Membrane Phospho-
lipid Hypothesis of schizophrenia resulted in a number
of double blind, placebo controlled intervention studies
in patients with schizophrenia. Initial studies were quite
small and were based on omega-6 PUFA, mainly gamma
linoleic acid, and the results were generally negative
[54]. Later, other n-3 PUFA were used in a series of
intervention trials.
A double blind placebo-conntrolled study by Peet et al.
[21] assessed the efficacy of add-on 12 week supplementa-
tion with 2 g/day EPA enriched oil, 2 g/day DHA enriched
oil or a corn oil placebo in reducing the intensity of symp-
toms in patients with chronic schizophrenia. At the end of
the trial, the PANSS score was significantly lower in the
EPA-supplemented patients than in the placebo group. No
significant differences were found between the DHA
enriched oil group and the placebo group. The same group
of researchers also tested the efficacy of 12-week supple-
mentation with 2 g/d EPA enriched oil as a sole treatment
for new or relapsed cases of schizophrenia who were not
treated with antipsychotics. After a 3-month intervention
period, the EPA-treated group had significantly lower
PANSS scores than the placebo group. Moreover, signifi-
cantly fewer EPA group patients required treatment with
antipsychotics at the end of the study and the length of
antipsychotic therapy was significantly shorter in the EPA
supplemented group than the placebo corn-oil group.Peet and Horrobin [24] followed up these early studies
with a dose-ranging placebo-controlled study of 1, 2 or
4 g/day of ethyl-EPA or liquid paraffin-placebo as add-
on therapy of chronic schizophrenia patients. The results
indicate that a dose of 2 g/day of ethyl-EPA used for
12 weeks significantly reduced psychopathology in com-
parison with placebo but only in patients treated with
atypical antipsychotic - clozapine. Doses of 1 and 4 g/day
for 12 weeks were not found efficacious.
Three other teams of researchers have assessed EPA
supplementation as add-on therapy in patients with
chronic schizophrenia using double-blind placebo con-
trolled trials. Fenton et al. [23] observed no significant
differences in the PANSS scores of chronic schizophre-
nia patients treated with either mineral oil placebo or
3 g/day ethyl-EPA for 16 weeks. However, RBC mem-
brane PUFA level significantly increased in both groups,
which could suggest that the participants consumed n-3
PUFA rich food or supplements during the trial. Another
trial by Emsley et al. [22] noted significantly higher reduc-
tion of PANSS scores in chronic medicated schizophrenia
patients receiving 12-week interventions of 3 g/day of
ethyl-EPA then those given paraffin oil placebo. The high-
est reduction was observed in patients treated with typical
antipsychotics.
Negative findings have also been found in chronic
schizophrenia patients. Norwegian researchers [55] re-
port generally negative results for 2 g/day of ethyl-EPA,
vitamin C (1000 mg/day) and vitamin E (364 mg/day)
for 16 weeks as add-on therapy of psychotic exacerba-
tion in chronic schizophrenia patients. The authors con-
clude that given separately during an acute episode, EPA
and vitamins E + C increased the severity of psychotic
symptoms in patients with low red blood cells (RBC)
levels of PUFA. When combined, the effect of these agents
on symptom severity was not significantly different from
placebo. No significant effects were observed for com-
bined EPA and vitamin C + E administration on PANSS
score in high-RBC PUFA level individuals.
Negative findings were also reported for the effect of
n-3 PUFA in first-episode schizophrenia patients. Another
group of researchers [26] assessed the effect of 2 g/day of
ethyl-EPA add-on therapy carried out for 12 weeks on
symptom severity in early psychosis. The study results did
not demonstrate a sustained symptomatic benefit of ethyl-
EPA in early psychosis, but ethyl-EPA was able to acceler-
ate treatment response and improve the tolerability of
antipsychotic medications. The authors argue that a ceil-
ing effect may have been responsible for the negative re-
sults of the study, since a high proportion of first-episode
patients already achieve symptomatic remission with anti-
psychotic medication alone.
Finally, n-3 PUFAs were assessed in individuals at ultra-
high risk (UHR) of psychosis. A randomized placebo-
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that 12-week supplementation with 1.2 g/day n-3 PUFA
(i.e. 700 mg of EPA and 440 mg/day of DHA) is effective
in preventing transition to full-threshold psychosis in
UHR individuals.
To sum up, the results of clinical trials of n-3 fatty acid
supplementation in chronic schizophrenia are inconsistent.
EPA was mainly used in the trials. The majority of positive
results were obtained with 12-week EPA supplementation
at daily doses of 2 and 3 g [21,22,24]. DHA alone was used
in one study conducted by Peet [21] and the results were
negative. One study based on first-episode schizophrenia
did not identify any positive effects of EPA on psychopath-
ology, possibly due to the ceiling effect [26]. A 12-week
supplementation with 1.2 g/daily of EPA +DHA was found
efficacious in preventing transition to full-threshold psych-
osis in individuals with clinical high risk of schizophrenia
development [56].
The rationale for using EPA supplementation to study
efficacy in early schizophrenia and relapse prevention is
mainly based on the findings of the chronic schizophre-
nia studies described above. The observation that EPA +
DHA add-on therapy could prevent psychotic disorder
development in UHR individuals supports an interven-
tion comprising both EPA and DHA. The rationale for
using DHA supplementation is based mainly on evidence
accumulating from basic, animal and human studies, indi-
cating that the DHA molecule has unique structural prop-
erties which appear to provide optimal conditions for a
wide range of cell membrane functions. This has particular
implications for grey matter, which is membrane-rich tis-
sue and abundant in DHA. A recently identified important
metabolic role played by DHA is the precursor for resol-
vins and protectins, both of which have anti-inflammatory
properties [57] and provide neuroprotection against oxida-
tive stress and apoptosis [58]. Oxidative stress and neuroin-
flammation has long been implicated in the pathogenesis
of schizophrenia. Since poor cognitive function was found
to be a risk factor for relapses of schizophrenia, it is signifi-
cant that it can be influenced by DHA. DHA was found to
improve cognition in healthy individuals [59,60] and in ani-
mal models [12,61], it has been found to be involved in
neurogenesis and neuroplasticity [62] and is thought to be
essential for neurodevelopment [48].
EPA and DHA supplementation was found to be effi-
cacious in an open label study of schizophrenia patients
treated with haloperidol [63]. Only one study addresses
the efficacy of n-3 PUFA administration in reducing re-
lapse rate in schizophrenia [43]. An intervention based
on 2 g of EPA plus 1 g of DHA and 300 mg of antioxidant
alpha-lipoic acid daily was used as the sole treatment in
stable schizophrenia patients whose antipsychotic therapy
was discontinued according to the current guidelines.
The results of the study were negative. No significantdifferences in relapse rate were found between the ac-
tive and placebo groups.
It is intended to use an intervention based on EPA and
DHA at a ratio of 1.5:1 by weight in the proposed
OFFER study. This form of intervention has not been
used so far in first-episode schizophrenia patients. In
addition, trials using only EPA supplementation have
returned inconsistent findings, and the RCT carried out
by Amminger et al. discussed above has already demon-
strated the efficacy of EPA +DHA in reducing the risk of
conversion to psychosis in individuals at ultra-high risk.
Hence, an OFFER study based on a long-term interven-
tion comprising both EPA and DHA as add-on therapy
appears to offer a great deal of potential.
Doses
The study participants will be supplemented with
1320 mg/day of EPA and 880 mg/day of DHA. Higher
doses of EPA and DHA will be used in the OFFER trial
than in the study led by Amminger et al., who assessed
transition to psychosis in individuals with high clinical
risk. It is assumed that the higher level of psychopath-
ology present in first episode schizophrenia patients
reflects higher PUFA metabolic abnormalities, which re-
quire higher doses of n-3 PUFA for normalization. The
doses of EPA and DHA intended to be used in the
present study have been found to be well tolerated and
safe in earlier studies of patients diagnosed with schizo-
phrenia [21].
Control condition
Olive oil was chosen as placebo because it contains
mainly monounsaturated fatty acids and only small
amounts of unsaturated and polyunsaturated fatty acids.
Previous studies used placebo composed of liquid paraf-
fin [22,24] and coconut oils [56], which are composed
mainly of unsaturated fatty acids. Since one of the sec-
ondary outcome measures in the OFFER study was a
change in the metabolic profile, an oil with low unsatur-
ated fatty acid content was chosen in order to avoid bias.
As the corn oil used in previous studies [21] contains
large quantities of omega-6 PUFA which negatively in-
fluences n-3 PUFA metabolism, it could influence the
main outcome by increasing the effect of the interven-
tion. However, since olive oil contains relatively small
amounts of linoleic acid (20:4, omega-6), and the fact
that it is a common constituent of the Polish diet, it is a
more suitable placebo. In addition, its familiarity as an in-
gredient has two further benefits: firstly, it could reduce
the risk of not giving consent, thus facilitating recruitment
by reducing patient concerns, and secondly, it may reduce
the non-compliance and attrition rates in the study. More-
over, it could be unethical to use placebo composed of
mainly monounsaturated fatty acids in FES patients, who
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treated with second generation antipsychotics.
Duration of intervention
The intervention period in the majority of the previous
studies assessing the efficacy of n-3 PUFA in schizophre-
nia lasted 8 to 12 weeks. No longer term trials were con-
ducted. The present study is planned to last 52 weeks
and will be composed of two phases: intervention and
follow-up. The intervention period is designed to be
continued for 26 weeks. Participants will be observed for
the 26 weeks following the intervention phase.
Medication adherence
For all patients, parent/patient self-report adherence
data will be collected regarding intervention and all psy-
chotropic medications at each medication visit. For par-
ticipants receiving study medication (i.e., n-3 PUFA or
placebo), information will also be collected by pill count
at all medication appointments.
Clinical outcome measures
Measures and assessment of outcomes
Clinical scales will be used to assess several domains of
symptoms and patient functioning. The severity of schizo-
phrenia symptoms will be measured using the Positive
and Negative Syndrome Scale [64], which is composed of
30 items scored 1–7, with a total score ranging from 30,
indicating an absence of psychopathology, to 208. PANSS
is a reliable and valid scale commonly used to score symp-
tom severity in schizophrenia [65].
Depressive features will be measured by the Calgary
Depression Scale for Schizophrenia (CDSS) that was de-
veloped specifically for schizophrenia patients [66]. It is
an observer-rated scale consisting of 9 items, each with
4 anchor points. The validity and reliability of the scale
was assessed in adults [67] as well as in adolescents [68].
Patient functioning status will be measured by means
of Global Assessment of Functioning (GAF) scale. The
GAF is a method for representing a clinician’s judgment
of a patient’s overall level of psychosocial functioning
[69]. The GAF requires a clinician to make an overall
judgment about a patient’s current psychological, social,
and occupational functioning. In the DSM-IV, this rating
is given on a scale from 1 to 100, with ratings of 1 to 10
indicating severe impairment and ratings of 91 to 100
indicating superior functioning.
The Clinical Global Impressions scale will be used to
measure symptom severity (CGI-S) and the range of im-
provement (CGI-I). CGI-S and CGI-I scales are commonly
used to assess efficacy of treatment in patients with mental
disorders [70]. The level of insight will be assessed with
the “My thoughts and feelings” questionnaire, whichwas validated in population of Polish patients with
schizophrenia [71].
All the raters have undertaken intensive training in the
scoring methods used in the study as part of the first
Polish program for people at high clinical risk of psych-
osis development (PORT), which is described in detail
elsewhere [72]. The raters achieved good reliability scores
(coefficient of agreement >0.82) and were all within 20%
of the standard scores.
Primary outcome measure
The primary outcome measure will be the efficacy of n-3
PUFA in reducing psychopathology in first-episode schizo-
phrenia. The Positive and Negative Syndrome Scale [64]
will be used to assess the efficacy of EPA +DHA supple-
mentation in reducing symptom severity in first-episode
schizophrenia after 8 and 26 weeks of supplementation.
The main outcome measure will be the change in symp-
tom severity from baseline to week 26. Baseline PANSS
total score will be subtracted from PANSS score obtained
after 26 weeks, resulting in the degree of change observed
in the study.
Another way of assessing the efficacy of n-3 PUFA in
reducing symptom severity in first-episode schizophrenia
patients will be the comparison of the number of re-
sponders in each intervention group: 25% and 50%
decreases in PANSS total score are considered cut-offs
for clinically significant symptom reduction and indi-
cates minimal and great improvement [73]. The percent-
age change of scores will be calculated according to
Leucht et al. [73], based on the principle that a patient
with no psychopathological symptoms scores 1 in all
PANSS scale items. The formula for calculating change
will be as follows: [(Pt2 – N) – (Pt1 – N)/(Pt1 – N)]•100,
where Pt1 is the PANSS subscale score at the beginning of
the study, Pt2 is the value at the end of the study and N is
the number of PANSS subscale items. N = 7 for PANSS
positive and negative subscales, N = 16 for the general psy-
chopathology PANSS subscale and N = 30 for the total
PANSS score. Patients who achieve at least a 25% reduc-
tion in the total PANSS score will be regarded as re-
sponders. Those who achieve a 50% decrease will be
regarded as much improved.
The first secondary aim
The secondary aim of the study is to assess whether
26 weeks intervention with 2.2 g of marine long-chain
n-3 polyunsaturated fatty acids initiated in the acute
phase of first episode schizophrenia can prevent relapse
during one year observation. Schizophrenia relapse will
be operationally defined as meeting any of one or more
of the following specified individual criteria given by
Csernansky et al. [74]: (a) a 25% increase in PANSS total
score; (b) deliberate self-injury; (c) emergence of clinically
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havior resulting in significant injury to another person or
significant property damage; (e) admission to psychiatric
inpatient clinic due to exacerbation. Since no common
agreement exists regarding the relapse criteria, the most
commonly used criteria were chosen on the basis of a
recent meta-analysis [75]. The presence of relapse will
be assessed during all study visits except for the first.
The chosen study design concerning relapses is more
pragmatic than explanatory and is used to reflect the
frequent clinical observation that patients treated for
first-episode schizophrenia achieve partial symptomatic
remission with persistence of certain symptoms after
the acute phase of the illness.
The second secondary aim
Other secondary clinical outcome measures include the
intensity of depressive symptoms, patient functioning,
symptom severity (CGI-S), the range of improvement
(CGI-I), and the level of insight.
Patients will also undergo dietary assessments at the
beginning of the study. This will enable control of that
possible confounder at the level of statistical analysis.
To address the third research question about the corre-
lates of the observed change, a number of assessments are
planned. Structural changes of the brain, i.e. cortical thick-
ness and fractional anisotropy of the white matter bundles,
will be measured using magnetic resonance imaging with
tensor diffusion. The level of PUFA metabolites (mainly
prostaglandins E2 and D2) will be measured indirectly by
using a niacin flush skin test (NFST) described in detail
elsewhere by Smesny et al. [76] Oxidative stress and
defense will be measured by the total oxidative plasma cap-
acity and 8-epi-alpha-izoprostanes. Neuroplasic changes of
the brain will be assessed indirectly by measuring the
plasma level of brain-derived neurotrophic factor (BDNF).
Metabolic syndrome components, i.e. weight, body mass
index (BMI), waist circumference, serum cholesterol con-
centration (total, LDL, HDL), serum triglyceride level, sys-
tolic and diastolic blood pressure will also be measured
during study visits. Descriptive variables will include so-
cioeconomic and demographic variables, variables con-
cerning psychiatric therapy and symptom duration, as
well as medical history.
Study visits
A total of 9 visits will be conducted, including a baseline
visit preceding commencement of study medication,
followed by 8 follow-up assessments at weeks 1, 2, 4, 6,
8, 16, 26, 52. Clinical assessments and measurements
comprising PANSS, CDSS, CGI-S, CGI-S, GAF, Question-
naire of Insight, and metabolic syndrome components, i.e.
weight, body mass index (BMI), waist circumference,
serum cholesterol concentration (total, LDL, HDL), serumtriglyceride level, systolic and diastolic blood pressure will
be carried out during the study visits. Correlates of change
will also be assessed, i.e. structural brain changes assessed
by means of MRI and biochemical measures of oxidative
stress and defense, as well as plasma BDNF concentration.
The complete schedule of assessments planned in the
OFFER trial is presented in Table 1.
Statistical methods and analytic plan
Primary aim
The primary aim is to assess the efficacy of add-on n-3
PUFA therapy in reducing the severity of symptoms in
schizophrenia patients after 26 weeks supplementation
accompanying standard antipsychotic treatment. Hence,
our primary outcome measure is the change observed
over time on the total and subscale PANSS scores. The
changes in the scores will be calculated by subtracting
baseline from follow-up score at each follow-up assessment
visit for each patient. Efficacy analyses will be performed
using the modified intent-to-treat (ITT) population, which
will consist of all randomized patients who will receive at
least one daily dose of either placebo or active compound
and have at least one efficacy evaluation on day seven or
later. Observed case analysis will also be performed for the
primary and secondary outcome measures.
Comparisons between treatment groups at baseline
will be conducted using a one-way analysis of covari-
ance, with intervention type as a term in the model and
duration of untreated psychosis (DUP) as covariate. The
distribution of socio-demographic characteristics in the
two treatment arms will also be compared to assess the
effectiveness of the randomization procedure.
To deal with missing values in our ITT sample, a mul-
tiple imputation technique will be used, in which a num-
ber of data sets are created, each with the missing values
replaced by some plausible values. The imputation of
the missing values is based on maximum likelihood and
Bayesian procedures and is performed by appropriate al-
gorithms. After the missing cases are completed by sev-
eral sets of plausible values to create multiple completed
datasets, standard complete-data procedures are applied
to each completed dataset, and finally the multiple sets
of results are combined to yield a single inference. The
multiple imputation technique is considered superior to
and less biased than the Last Observation Carried For-
ward (LOCF) [53,77].
The analysis of covariance (ANCOVA) with interven-
tion type as term and baseline PANSS score as covariate
will be used to assess the change from baseline in
PANSS scores to week 8 and 26 separately. If the overall
ANCOVA of the baseline-to-endpoint change score will
be significant, pairwise comparison will be performed
using Dunnett t test. Analyzes will be two-sided for both
ANCOVA and Dunnett test with the type I error rate
Table 1 Schedule of the study visits and planned assessments in OFFER trial
ID Variable Study visits V1 V2 V3 V4 V5 V6 V7 V8 V9
Week 0 1 2 4 6 8 16 26 52
1 Clinical measures PANSS X X X X X X X X X
CGI-S X X X X X X X X X
CGI-I X X X X X X X X X
CDSS X X X X X X X X X
GAF X X X X X X X X X
2 Insight questionnaire “My thoughts and feelings” X X X X
3 Prostaglandin synthesis (PGD2, PGE2) Niacin flush skin test X X X
4 Cognitive function tests: Working
memory and Executive functions
TMT Part A and B, and their alternate
forms, i.e. Part C, D and Digit Span
Forward and Backward
X X X
Verbal memory CVLT X X X
Visual memory BVRT X X X
Abstract thinking Halstead Category Test X X X
Verbal fluency Semantic and Phonological X X X
5 Magnetic Resonance Imaging Grey matter thickness - VBM X X
Fractional anisotropy – DTI X X
6 Oxidative stress Isoprostane 8-epi-PGF2alpha (plasma) X X X
Antioxidative defense Total plasma antioxidative capacity X X X
7 Neuronal plasticity Plasma BDNF concentration X X X
8 Dietary questionnaire Diet history questionnaire X
9 Metabolic syndrome traits Plasma lipid profile X X X X
(biochemical assessments) Fasting Blood Glucose level X X X X
10 Metabolic syndrome traits Body weight X X X X X X X X X
Waist circumference X X X X X X X X X
(clinical measures) Blood pressure X X X X X X X X X
Abbreviations: PANSS – Positive and Negative Syndrome Scale, CGI-S - Clinical Global Impressions - Severity, CGI-I - Clinical Global Impressions - Improvement,
CDSS - Calgary Depression Scale for Schizophrenia, GAF – Global Assessment of Functioning, PGD2 – Prostaglandin D2, PGE2 - Prostaglandin E2, TMT – Trail
Making Test Part, CVLT – California Verbal Learning Test, BVRT - Benton Visual Retention Test , VBM – Voxel Based Morphometry, DTI –Diffusion tensor Imaging,
8epiPGF2alpha – plasma concentration of prostaglandin 8-epi-F-2alpha, BDNF – plasma concentration of brain derived neurotrophic factor.
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lyses will be repeated to assess the significance of differ-
ences in changes of CDSS, CGI and GAF scores between
the study arms.
Secondary aim
The secondary outcome of the study will be the efficacy
of n-3 PUFA to prevent relapse in first-episode schizo-
phrenia. Hence, the secondary null hypothesis will be
that intervention is not different from placebo on the ef-
ficacy measure. Using the relapse rate as the secondary
endpoint a one-sided log-rank test with an overall sam-
ple size of 82 subjects (41 per study arm) will achieve a
90.2 % power at a 0.05 significance level to detect a dif-
ference of 20 percentage points (regarded as clinically
significant) in the relapse rate. Intention-to-Treat basis
(ITT) will be used in analyses. Analysis of secondary end-
point will be by the Last Observation Carried Forward(LOCF) principle. The secondary outcome measure will
be interpreted at 0.05 significance level.
Safety and tolerability
All adverse events volunteered or observed during the
study will be recorded, together with their severity and dur-
ation during all assessment visits. Tolerability will be mea-
sured with the Udvalg Kliniske Udersogelser Side Effect
Rating Scale (UKU) [78], a semistructured interview for the
assessment of the general side effects of psychotropic medi-
cation. The emergance and severity of extrapiramidal symp-
toms will be measured using the Simpson-Angus Scale
(SAS) [79], and the Barnes akathisia scale (BAS) [80].
Discussion
Design weakness and limitations
The main limitation of the study is that it is not possible
to measure the concentration of n-3 PUFA in the red
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to verify study medication adherence. To account for
this, pill counts will be taken and data will be collected
concerning medication adherence during every study
visit. However, the randomization and blinding used in
the study design indicates that the possible bias intro-
duced at this level can be distributed equally between
the study arms. However, the effect of the intervention
may be decreased because of possible adherence prob-
lems, which can be difficult to detect.Methodological considerations
The current study has several strengths, including
randomization of patients and blinding of both patients
and staff. The used design (RCT) is the standard for the
evaluation of efficacy of psychiatric treatments. The use
of a longitudinal design also makes it possible to assess
change and observe the postulated correlates of change.
Another strength of the study is the composition of n-3
PUFA used, i.e. a 1.5:1 mixture of EPA and DHA, which
has not yet been used in patients with first-episode schizo-
phrenia. The dosage of PUFA supplementation is higher
than in previous studies and low enough to assure safety
of intervention. The length of the supplementation period
is rather long in comparison with previous studies and
equals six months, which enables both short and long-
term efficacy assessment. The follow-up period after fin-
ishing supplementation makes it possible to assess the
relapse rate after first-episode of schizophrenia. Finally the
intervention is delivered to individuals with relatively
short periods of the disease. Most of the above mentioned
characteristics make the present study considerably differ-
ent from the previous studies and constitute the advan-
tages of the study design.Conclusion
It is intended to perform a randomized, double-blind,
placebo-controlled, parallel-group single-center, six month,
augmentation trial (RCT) of an intervention based on 2.2 g
of EPA +DHA added on to an adjustable dose of anti-
psychotic medication in patients with first-episode schizo-
phrenia. The main outcome measure will be the efficacy of
n-3 PUFA in reducing symptom severity measured by
means of PANSS. The secondary outcome measures con-
stitute the following: (a) the efficacy of 6-month add-on
therapy with n-3 PUFA in reducing the risk of relapse in
first-episode schizophrenia patients during the first year of
therapy; (b) the influence of n-3 PUFA on depressive
symptoms, general functioning and level of insight. With
its longitudinal design, the study aims also to observe cor-
relates of the expected change, i.e. structural brain changes
observed in MRI scans, oxidative stress and defense mech-
anisms as well as brain plasticity.Competing interests
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